These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 6580554

  • 1. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
    Willemze R, Fibbe WE, Zwaan FE.
    Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
    [No Abstract] [Full Text] [Related]

  • 2. [A case of refractory acute lymphocytic leukemia responded to an intermediate-dose of cytosine arabinoside (ID Ara-C) therapy].
    Hirota Y, Shibuya T, Ohhara N, Okamura S, Iwagiri R, Tada Y, Otsuka T, Nagano M, Tsuda Y, Niho Y.
    Rinsho Ketsueki; 1986 Jun; 27(6):941-6. PubMed ID: 3463812
    [No Abstract] [Full Text] [Related]

  • 3. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F, Tejima Y, Tajima H, Lee SY, Shiozaki A, Nakai R, Chyosa M, Sawada T, Maeda Y, Mizokuni T.
    Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
    [No Abstract] [Full Text] [Related]

  • 4. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
    Shimazaki C, Fujita N, Nakanishi S, Nishio A, Haruyama H, Nakagawa M, Ijichi H.
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
    [Abstract] [Full Text] [Related]

  • 5. Treatment of refractory acute leukemia with high-dose chemotherapy.
    Kramer BS, Appelbaum FR, Herzig GP, Graw RG, Levine AS.
    Cancer Treat Rep; 1977 Oct; 61(7):1397-8. PubMed ID: 271045
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA, Children's Cancer Group Study 2951.
    J Clin Oncol; 2003 Aug 01; 21(15):2940-7. PubMed ID: 12885813
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
    Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B.
    Semin Hematol; 1991 Jul 01; 28(3 Suppl 4):35-8. PubMed ID: 1780750
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of refractory acute leukaemia with high dose cytosine arabinoside.
    Willemze R, Zwaan FE, Keuning JJ, Colpin G.
    Br J Haematol; 1982 Jul 01; 51(3):497-8. PubMed ID: 6954973
    [No Abstract] [Full Text] [Related]

  • 12. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E, Koc Y, Kars A, Alakavuklar M, Tekuzman G, Firat D.
    J Chemother; 1989 Jul 01; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract] [Full Text] [Related]

  • 13. High-dose cytosine arabinoside in the treatment of childhood malignancies.
    Lie SO, Slørdahl S.
    Semin Oncol; 1985 Jun 01; 12(2 Suppl 3):160-5. PubMed ID: 3859931
    [No Abstract] [Full Text] [Related]

  • 14. [Acute adult leukemia: experience with 41 patients].
    Gutiérrez J, Bronfman L, Torrens M, Jara O, Lorca J, Barria M.
    Rev Med Chil; 1987 Jun 01; 115(6):530-8. PubMed ID: 3483249
    [No Abstract] [Full Text] [Related]

  • 15. [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
    Li QH, DU X, Huang ZL, Luo CW, Zhong LY, Lin W.
    Zhonghua Yi Xue Za Zhi; 2005 May 11; 85(17):1195-7. PubMed ID: 16029595
    [Abstract] [Full Text] [Related]

  • 16. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia.
    Neri A, Comis M, Brugiatelli M, Martino B, Ronco F.
    Haematologica; 1989 May 11; 74(1):113-4. PubMed ID: 2498174
    [No Abstract] [Full Text] [Related]

  • 17. Chemotherapy of acute myeloblastic leukaemia with DAM regimen.
    Yunus AB, Sayeed MA, Barua A, Rahman J, Rashid MA.
    Bangladesh Med Res Counc Bull; 1997 Dec 11; 23(3):82-6. PubMed ID: 9621477
    [Abstract] [Full Text] [Related]

  • 18. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
    Kawada H, Komatsuda M, Masumoto A, Fukuda R, Watanabe S, Yonekura S, Ichikawa Y, Nagao T, Arimori S.
    Rinsho Ketsueki; 1993 May 11; 34(5):667-9. PubMed ID: 8315839
    [Abstract] [Full Text] [Related]

  • 19. [Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone].
    Marín P, Grañena A, Carreras E, Ribera JM, Rozman C.
    Sangre (Barc); 1984 May 11; 29(6):987-92. PubMed ID: 6598237
    [No Abstract] [Full Text] [Related]

  • 20. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S, Pandita R, Bavishi K, Savani B.
    Neoplasma; 1999 May 11; 46(1):61-5. PubMed ID: 10355536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.